Eli Lilly's Zepbound surpasses Novo Nordisk's Wegovy in US prescription sales for the first time.
Eli Lilly's Zepbound outpaced Novo Nordisk's Wegovy in US prescriptions for the first time since launch, suggesting Eli Lilly may be winning the war on weight loss drugs. The data, released recently, illustrates the power of Eli Lilly's product portfolio. Despite Zepbound not being its fastest-growing treatment, sales for its cancer drug Verzenio increased by 56% year-on-year in 2023, reaching $3.8 billion.
March 20, 2024
4 Articles